DaxibotulinumtoxinA

Generic Name: DaxibotulinumtoxinA

Brand Names: Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin

Drug Type: Biotech

Chemical Formula: -

CAS Number: 93384-43-1

Unique Ingredient Identifier: E211KPY694

Background: DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.

DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.

Indication: DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.

Associated Conditions: Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)

Associated Therapies: -

Clinical Trials

Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder

Vensica Medical secures $11M to fund Phase 2 trials for OAB treatment using Xeomin® via a needle-free device.

americanmedspa.org

2 months ago

Botox Cosmetic (onabotulinumtoxinA) Receives FDA Approval for New Aesthetic Indication

Allergan Aesthetics, an AbbVie company, received U.S. FDA approval for Botox Cosmetic to temporarily improve the appearance of moderate to severe platysma bands in adults. This marks Botox Cosmetic as the first product with four aesthetic indication areas, offering a nonsurgical, injectable option for vertical bands connecting the jaw and neck.

ipsen.com

3 months ago

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full ...

Ipsen reports YTD 2024 total sales growth of 9.2% at CER, driven by Dysport, Cabometyx, and Bylvay. Regulatory approvals for Iqirvo and Kayfanda, and increased 2024 guidance: total-sales growth >8.0% at CER, core operating margin >31.0%.

pharmexec.com

3 months ago

FDA Approves Allergan Aesthetics' Botox Cosmetic for Moderate to Severe Vertical Platysma Bands

FDA approves Allergan Aesthetics' Botox Cosmetic for treating moderate to severe vertical platysma bands, offering a nonsurgical option for neck band improvement. Phase III studies showed significant improvement and patient satisfaction. Potential adverse effects include excessive weakness and dysphagia.

healio.com

3 months ago

FDA approves Botox Cosmetic for platysma bands

FDA approves Botox Cosmetic for platysma bands, marking the first neurotoxin for this use and expanding its aesthetic indications to four.

newbeauty.com

3 months ago

Botox Receives FDA Approval for Treating Neck Bands

Botox Cosmetic receives FDA approval for treating moderate to severe vertical neck bands (platysmal bands), marking its first approval beyond facial areas. This new use allows for complete rejuvenation, including the neck, with doses of 26, 31, or 36 units depending on severity. Botox now has four FDA-approved aesthetic uses: forehead lines, frown lines, crow’s feet, and platysmal bands.

biospace.com

3 months ago

New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of ...

Galderma announces phase III READY-4 trial data showing long-term safety of RelabotulinumtoxinA for frown lines and crow’s feet, with efficacy and patient satisfaction maintained across multiple treatments. The study met primary and secondary endpoints, with mild or moderate treatment-emergent adverse events reported by 18% of participants. RelabotulinumtoxinA, developed using PEARL™ Technology, is the first ready-to-use liquid neuromodulator optimized for simple volumetric dosing.

Related Clinical Trials:

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy